auristatin

McMMAF is a protective group-conjugated MMAF. MMAF is a potent tubulin polymerization inhibitor.It is a MMAF derivative having a Maleimidocaproyl linker (MC linker), which is ready to conjugate to antibody or other proteins or biopolymers. Mafodotin is a useful agent for make antibody drug conjugate (ADC) for targeted drug delivery.

Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE . MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization[1].

Monomethyl auristatin E (MMAE) (MMAE), an antimitotic agent, inhibits cell division by blocking the polymerization of tubulin and also has inhibition of antibody-drug conjugates (ADCs) activity.

Auristatin F is an effective inhibitor of microtubule and vascular damaging agent. Auristatin F can be used in antibody-drug conjugates.

MC-Val-Cit-PAB-Auristatin E is an antibody-drug conjugate (ADC) linker compound with Auristatin E, a potent cytotoxic tubulin modifier, attached via the MC-Val-Cit-PAB linker, demonstrating significant antitumor activity.

Mc-MMAE (Maleimidocaproyl-monomethylauristatin E) is a drug-linker conjugate for ADC. Mc-MMAE is a maleimidocaproyl-conjugated monomethyl auristatin E, which is a potent tubulin inhibitor.

MMAF-OMe (Monomethyl auristatin F methyl ester) is an antitubulin agent which inhibits several tumor cell lines with IC50s of 0.056 nM, 0.166 nM, 0.183 nM, and 0.449 nM for MDAMB435 5T4, MDAMB361DYT2, MDAMB468, and Raji (5T4-) cell lines, respectively. MMAF-Ome is also an ADC cytotoxin.

m-PEG4-Br is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADC) for Trastuzumab, positioned distally from the monomethyl auristatin E (MMAE) payload to produce an ADC with modified hydrophilicity, antigen binding, and in vitro potency[1].

Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) is a drug-linker conjugate for antibody-drug conjugates (ADCs), combining the ADC linker (Acetylene-linker-Val-Cit-PABC) with the potent tubulin inhibitor MMAE.

AcLys-PABC-VC-Aur0101 is a drug-linker conjugate for anti-CXCR4 ADC, exhibiting potent antitumor activity and comprising the auristatin microtubule inhibitor Aur0101, connected through the cleavable linker AcLys-PABC-VC[1].

AmPEG6C2-Aur0131 is a drug-linker conjugate designed for anti-CXCR4 ADC applications, showcasing potent antitumor activity. It incorporates Aur0131, an auristatin-based microtubule inhibitor, connected through the non-cleavable AmPEG6C2 linker.

Cys-mcMMAD is a drug-linker conjugate for ADC (antibody-drug conjugate) featuring MMAD, a potent tubulin inhibitor.

DBCO-(PEG2-VC-PAB-MMAE)2 consists of Monomethyl auristatin E (MMAE), a potent tubulin inhibitor and toxin payload in antibody-drug conjugate [1], conjugated to the cleavable linker DBCO-(PEG2-VC-PAB)2, serving as the cytotoxic component in this formulation.

DBCO-(PEG)3-VC-PAB-MMAE is a chemical compound where monomethyl auristatin E (MMAE), a potent tubulin inhibitor used as a toxin payload in antibody-drug conjugates, is conjugated via a DBCO-(PEG)3-vc-PAB linker.

Fmoc-Val-Cit-PAB-MMAE is consisted of the ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). Fmoc-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC.

MAL-di-EG-Val-Cit-PAB-MMAE consists of the linker MAL-di-EG-Val-Cit-PAB and the potent tubulin inhibitor MMAE, both of which are crucial components of antibody-drug conjugates (ADCs).

MAL-di-EG-Val-Cit-PAB-MMAF is a chemical compound consisting of the linker (MAL-di-EG-Val-Cit-PAB) and the potent tubulin polymerization inhibitor (MMAF, Monomethyl auristatin F) [1].

Mal-Phe-C4-VC-PAB-MMAE is a chemical compound formed by conjugating monomethyl auristatin E (MMAE), a potent tubulin inhibitor used as a toxin payload in antibody-drug conjugates, with a Mal-Phe-C4-VC-PAB linker.

MC-Alkyl-Hydrazine Modified MMAF is a potent antitumor drug-linker conjugate for ADC, utilizing Modified MMAF, a tubulin inhibitor, connected via a noncleavable MC-Alkyl-Hydrazine linkage[1].

Mc-MMAD, a drug-linker conjugate for antibody-drug conjugates (ADCs), incorporates the protective group maleimidocaproyl (Mc) conjugated to monomethyl auristatin D (MMAD), a potent inhibitor of tubulin.

MC-Sq-Cit-PAB-Dolastatin10 is a potent antitumor drug-linker conjugate for Antibody-Drug Conjugates (ADC), incorporating Dolastatin10 (a tubulin polymerization inhibitor) connected via the MC-Sq-Cit-PAB ADC linker.

MC-Val-Cit-PAB-MMAF is an antibody-drug conjugate (ADC) component that exhibits antitumor properties through the action of the tubulin inhibitor, monomethyl auristatin F (MMAF), which is connected by a cathepsin-cleavable linker, MC-Val-Cit-PAB.

MC-VC-PABC-Aur0101 is a potent anticancer drug-linker conjugate for Antibody-Drug Conjugates (ADCs), incorporating Aur0101, an auristatin microtubule inhibitor, linked via the MC-VC-PABC linker to boost antitumor efficacy.

MMAE-SMCC is a drug-linker conjugate designed for antibody-drug conjugates (ADC). It consists of MMAE, a potent inhibitor of mitosis and tubulin, and SMCC, a linker that facilitates the development of ADCs.